Shamburg News · 8-K filed Nov 2, 2026, 6:47 AM EST

Atrium Therapeutics Presents Nonclinical Data on ATR 1072 for PRKAG2 Syndrome at HCMS 2026

RNA · Atrium Therapeutics, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: low

On November 2, 2026, Atrium Therapeutics, Inc. announced it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for PRKAG2 syndrome at the Hypertrophic Cardiomyopathy Medical Society meeting during the American Heart Association Scientific Sessions 2026 on November 6, 2026 in Chicago, Illinois. The data, generated in a new mouse model using the surrogate mATR 1072, showed reversal of cardiac glycogen accumulation and improvement in hypertrophy and ECG parameters. The company also updated its corporate presentation as of the same date and furnished it as Exhibit 99.2.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-442601.

Written from the filing by Shamburg Markets. Figures are as reported by the company.